HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer

Investigational New Drugs

Volumn 32, Issue 2, 2014, Pages 235-242

  Sonpavde, Guru ^a,b   Wang, Mingjun ^c   Peterson, Leif E ^c   Wang, Helen Y ^c   Joe, Teresa ^b   Mims, Martha P ^a   Kadmon, Dov ^a   Ittmann, Michael M ^a,b   Wheeler, Thomas M ^a   Gee, Adrian P ^d   Wang, Rong Fu ^c   Hayes, Teresa G ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Cancer vaccines; Castration resistant prostate cancer; HLA restricted; Immunotherapy; NY ESO 1; Peptide

Indexed keywords

CANCER VACCINE; DOCETAXEL; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 2; HLA DP4 ANTIGEN; HLA DR4 ANTIGEN; PEPTIDE VACCINE; PROLYLGLYCYLVALYLLEUCYLLEUCYLLYSYLGLUTAMYLPHENYLALANYLTHREONYLVALYLSERYLGLYCINE VACCINE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SERYLLEUCYLLEUCYLMETHIONYLTRYPTOPHYLISOLEUCYLTHREONYLGLUTAMINYLCYSTEINE VACCINE; TYROSYLGLYCYLARGINYLLYSYLLYSYLARGINYLARGINYLGLUTAMINYLARGINYLARGINYLSERYLLEUCYLLEUCYLMETHIONYLTRYPTOPHYLISOLEUCYLTHREONYLGLUTAMINYLALANYLPHENYLALANYLLEUCYLPROLYLVALINE VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANOREXIA; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELLULAR IMMUNITY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENZYME LINKED IMMUNOSPOT ASSAY; EOSINOPHILIA; FATIGUE; FLU LIKE SYNDROME; FUNCTIONAL ASSESSMENT; HAPLOTYPE; HEART INFARCTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INJECTION SITE ERYTHEMA; LEUKOCYTOSIS; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; METASTASIS POTENTIAL; MYALGIA; NAUSEA; NEUTROPHILIA; PAIN; PHASE 1 CLINICAL TRIAL; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T LYMPHOCYTE ACTIVATION; TACHYCARDIA; THORAX PAIN; TOXICITY TESTING; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CANCER VACCINES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PEPTIDES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; T-LYMPHOCYTES;

EID: 84896405689     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9960-9     Document Type: Article

References (31)

1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363:411-22
2. Jungbluth AA, Chen YT, Stockert E et al (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer J Int Cancer 92:856-860
3. Odunsi K, Jungbluth AA, Stockert E et al (2003) NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 63:6076-6083
4. Chen YT, Scanlan MJ, Sahin U et al (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 94:1914-1918
5. Jager E, Nagata Y, Gnjatic S et al (2000) Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A 97:4760-4765
6. Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA (1998) A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol 161:3598-3606
7. Jager E, Karbach J, Gnjatic S et al (2006) Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A 103:14453-14458
8. Fossa A, Berner A, Fossa SD, Hernes E, Gaudernack G, Smeland EB (2004) NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 59:440-447
9. Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF (2000) Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol 165:1153-1159
10. Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF (2001) CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A 98:3964-3969
11. Zeng G, Li Y, El-Gamil M et al (2002) Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 62:3630-3635
12. Rosenberg SA, Yang JC, Schwartzentruber DJ et al (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327
13. Jager E, Gnjatic S, Nagata Y et al (2000) Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 97:12198-12203
14. Marchand M, van Baren N, Weynants P et al (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer J Int Cancer 80:219-230
15. Dutoit V, Taub RN, Papadopoulos KP et al (2002) Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest 110:1813-1822
16. Khong HT, Yang JC, Topalian SL et al (2004) Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother 27:472-477
17. Jager E, Chen YT, Drijfhout JW et al (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265-270
18. Jager E, Jager D, Karbach J et al (2000) Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101- 0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 191:625-630
19. Rini BI, Weinberg V, Bok R, Small EJ (2003) Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 21:99-105
20. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422
21. Rosenberg SA, Yang JC, Schwartzentruber DJ et al (1999) Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 163:1690-1695
22. Disis ML, Grabstein KH, Sleath PR, Cheever MA (1999) Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res: Off J Am Assoc Cancer Res 5:1289-1297
23. Muderspach L, Wilczynski S, Roman L et al (2000) A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res: Off J Am Assoc Cancer Res 6:3406-3416
24. Wang M, Lamberth K, Harndahl M et al (2007) CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Vaccine 25:2823-2831
25. Maio M, Coral S, Sigalotti L et al (2003) Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J Clin Endocrinol Metab 88:748-754
26. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 39:D913-9
27. Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159
28. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M (2007) A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13:6396-6403
29. Arlen PM, Bianco F, Dahut WL et al (2008) Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 179:2181-2185, discussion 5-6
30. Hoos A, Eggermont AM, Janetzki S et al (2010) Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102:1388-1397
31. Noguchi M, Kakuma T, Uemura H, et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother. 59:1001-9